Important communication to NERIVIO® patients and users
Discontinuation of the marketing of NERIVIO® in Spain
End of marketingOctober 31, 2026
Customer support untilJanuary 31, 2027
Dear Patient,
Reddy Pharma Iberia, S.A. would like to inform you that, as of October 31, 2026, the medical device NERIVIO® will no longer be marketed in Spain.
This decision is based exclusively on business and commercial reasons and is not related to any issue concerning the quality, safety, or effectiveness of the product.
We understand the importance that NERIVIO® has had for many people in managing their migraine, and we regret any inconvenience this situation may cause.
If you are currently using NERIVIO®, we recommend that you contact your specialist physician or regular healthcare professional well in advance to evaluate the available therapeutic alternatives that best suit your clinical situation.
Although the marketing of the product will cease on October 31, 2026, Reddy Pharma Iberia, S.A. will continue to provide customer support and manage inquiries related to NERIVIO® until January 31, 2027.
For any questions, please contact us:
Reddy Pharma Iberia, S.A. – Patient Support Department
We would like to sincerely thank you for the trust you have placed in NERIVIO® and in our company during this time.
Yours sincerely, Reddy Pharma Iberia, S.A.
Important Notice: This communication is intended solely to inform patients and users about the discontinuation of the marketing of NERIVIO® in Spain, effective October 31, 2026. Patients should not discontinue or modify any treatment without first consulting their healthcare professional. Any personal data provided when contacting our customer support service will be processed in accordance with applicable data protection legislation.
Choosing a selection results in a full page refresh.
